Cargando…
TP53 Signature Can Predict Pathological Response From Neoadjuvant Chemotherapy and Is a Prognostic Factor in Patients With Residual Disease
BACKGROUND: The TP53 signature that predicts the mutation status of TP53 has been shown to be a prognostic factor and predictor of neoadjuvant chemotherapy (NAC) response. OBJECTIVES: The current study sought to investigate the utility of the TP53 signature for predicting pathological complete respo...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170595/ https://www.ncbi.nlm.nih.gov/pubmed/37181950 http://dx.doi.org/10.1177/11782234231167655 |